Collegium (COLL) FCF Analysis: Owner Earnings Test

FCF Performance Summary

Market Cap: $944M  |  Enterprise Value: $1.91B  |  Price: $29.11 (as of August 6, 2026)

Cash Generation Quality

By the crudest earnings-quality test — free cash flow divided by net income — Collegium looks almost too good: FCF of $328 million against GAAP net income of just $62.9 million in 2025 is a 521% conversion ratio. That gap is not a red flag on its own; it is mechanical. GAAP net income is struck after $221.9 million of acquisition-related intangible amortization, a large non-cash charge that has nothing to do with the cash actually collected from Belbuca, Xtampza, Nucynta, Jornay PM or Azstarys sales. Compared against adjusted net income, which already excludes that amortization, FCF conversion is a far more ordinary 113%.

Stock-based compensation is a real but shrinking claim on the cash: $41.9 million in 2025, down from 25% of FCF in 2020 to about 13% today. FCF after SBC was $286 million in 2025, still a 30.3% yield on the current market cap — dilution is a modest drag here, not a structural one.

The more interesting number is FCF-to-operating-cash-flow conversion, which has run 94–100% every year since 2020 and 99–100% since 2022, because capex intensity has fallen from 1.8% of revenue in 2020 to 0.2% today and shows no sign of creeping back. That is the mark of an asset-light licensing and commercialization model: there is no factory to maintain, no heavy fixed-asset base eating into cash. The tradeoff, covered below, is that the reinvestment this business actually needs shows up as acquisitions financed with debt, not as capex on the cash flow statement.

FY2025 Capital Allocation Breakdown

Collegium directed only 7.6% of 2025's free cash flow to buybacks, with the large majority retained on the balance sheet — net debt actually fell to $423 million at the end of 2025 from $786 million a year earlier. That retention did not last: the $655.6 million cash-and-debt-funded Azstarys acquisition closed in May 2026, pushing net debt to $962 million and leverage to 2.1x adjusted EBITDA by the end of the second quarter. Read across the full 2020–2026 window rather than one year at a time, capital allocation here has one dominant use: acquisitions, funded substantially by debt, with buybacks and organic deleveraging absorbing whatever cash is left between deals.

6-Year FCF Trend Analysis (FY2020–FY2025)

The trajectory is a step function driven by acquisitions rather than a smooth compounding curve, with one real down year in the middle of an otherwise sharp climb.

         FY2020    FY2021    FY2022    FY2023    FY2024    FY2025
         $88M      $102M     $123M     $274M     $203M     $328M

  5Y CAGR (20-25): 30.1%  |  3Y CAGR (22-25): 38.7%  |  5-Yr Avg (21-25): $206M

Trend Narrative

Through 2021, Collegium ran a single-product-era base — Nucynta, Xtampza ER and Symproic — generating $88–102 million of FCF with capex already falling toward negligible levels. The 2022 acquisition of BioDelivery Sciences (Belbuca) roughly doubled revenue, and after a year of integration drag, free cash flow jumped 124% to $274 million in 2023 as the combined portfolio's cash conversion normalized.

2024 is the year that complicates a simple growth story: FCF fell 26% to $203 million even though the underlying pain and ADHD franchises were not deteriorating operationally. The decline tracks the Ironshore acquisition (Jornay PM) and the financing costs of carrying more debt, not a falloff in the business itself — a useful reminder that in a serial-acquirer model, a down year in FCF doesn't necessarily mean a down year in the operating business.

2025 recovered to $328 million, up 61.6%, and that figure has essentially held through the trailing twelve months to June 2026. Consensus estimates going into the analysis had 2026 roughly flat at $339 million, but those estimates were pulled the day after Collegium's August 6, 2026 guidance cut and had not yet absorbed it — a gap worth flagging rather than passing through as fact. Structurally, none of the 2022–2025 improvement came from working-capital releases or cost efficiency; it came almost entirely from acquired revenue, which means the forward trajectory depends on the deal pipeline continuing, not on operating leverage still waiting to be harvested.

Operating Cash Flow and Amortization Context

Note: Collegium does not separately break out a standard depreciation-and-amortization line comparable across periods in XBRL; the figures above are acquisition-related intangible amortization as disclosed in the company's adjusted-earnings reconciliations. This amortization is the closest available proxy for the cost of replacing the acquired drug portfolio as it decays — see the FCF Quality Score discussion below for why that distinction matters.

Capital Expenditure Profile

Capex intensity has fallen by a factor of nine since 2020 and has stayed near zero for four consecutive years. There is no hidden reinvestment building up inside this line item, which is unusual for a company of this size — and it is also the whole reason the "free cash flow" and "owner earnings" numbers in this analysis diverge so sharply. A pharmaceutical company that develops its own drugs would run heavier R&D and capex through the P&L and cash flow statement as it replaces its pipeline. Collegium replaces its pipeline by acquisition instead, so that cost shows up as intangible amortization and debt-funded M&A rather than as capex.

FCF Quality Score: 7/10 — High Quality, Structurally Levered

A 7/10 reflects two things pulling in opposite directions. The mechanics of cash conversion here are about as clean as this metric gets: FCF/OCF above 94% every year since 2020, capex that has fallen to a rounding error, and shrinking stock-based compensation as a share of the total. That combination is genuinely rare and earns real credit. What holds the score back from the 8–9 range is that the mechanical cleanliness obscures a more important economic question — whether the cash being generated is actually free, or whether a meaningful share of it needs to be reinvested just to keep the portfolio from shrinking.

The case for the higher end of the range: FCF/OCF conversion in the high nineties for four straight years, capex at 0.2% of revenue with no sign of reversal, and SBC that has fallen from a quarter of FCF in 2020 to about 13% now. Revenue growth of roughly 20% annually from 2020 to 2025, even if acquisition-driven, has been funded without diluting shareholders materially — shares outstanding actually declined from 34.2 million to 31.7 million over the period.

The case against a higher score centers on what the reported free cash flow doesn't charge for. Collegium spends almost nothing on R&D or capex because it buys finished, marketed drugs instead of developing them, and those acquired assets decay — Nucynta revenue fell 24% year-over-year in the most recent quarter as authorized generics eroded pricing. Treating $221.9 million of 2025 intangible amortization as the real cost of standing still — an "owner earnings" adjustment in the tradition Warren Buffett described, discussed further in Owner Earnings vs. Free Cash Flow — cuts the yield from 34.8% to roughly 11–13%. That's still above a 10% hurdle, but with far less margin than the headline number implies.

The structural risk that caps the score is leverage. Net debt/EBITDA moved from 0.9x at the end of 2025 to 2.1x by the end of the second quarter of 2026 to fund the Azstarys acquisition, and gross debt now stands at roughly $1.09 billion against a $944 million market capitalization — equity is only about half of enterprise value. A company whose reinvestment need is disguised as M&A rather than capex, funded increasingly with debt, is taking on a risk profile that a simple FCF/OCF ratio does not capture. If the next acquisition is priced meaningfully above the roughly 6.8x acquired EBITDA implied by the last four deals, the owner-earnings math gets worse, not better.

Forward Outlook: Key Scenarios

The primary variable is the balance between two forces moving in opposite directions: the pace at which the pain portfolio (Nucynta, Xtampza ER, Belbuca) erodes, and the growth rate of the ADHD portfolio (Jornay PM, Azstarys) acquired to replace it.

Scenarios are built at a 10% cost of equity with exit FCF yields set above the hurdle rate to reflect the finite life of an amortizing drug portfolio; they are illustrative, not price targets. For context, a reverse-engineered read of the current $29.11 price implies the market is discounting roughly a 25% annual decline in the $328 million LTM free cash flow figure — a materially harsher assumption than the base case above, and roughly in line with the current pace of Nucynta's decline alone rather than the whole portfolio.

Catalysts to Monitor

The Nucynta authorized-generic decay rate is the single most-watched near-term number: it fell 24% year-over-year in the second quarter of 2026 and was the direct cause of the August 6 guidance cut, with authorized-generic pricing now disclosed at 10–15% of branded net price for the immediate-release form and 20–25% for extended-release. A second guidance cut, or evidence that Xtampza ER's 14% quarterly decline is a trend rather than noise, would be a materially different signal than the current base case.

Azstarys and Jornay PM together carry the offsetting growth thesis. Jornay PM grew 41% year-over-year in the most recent quarter against a management-held guide of $190–200 million for the year, and Azstarys was guided to $65–75 million for its partial first year following the May 2026 acquisition. Whether ADHD growth continues to outpace pain-portfolio decay determines which side of the base case this settles on.

Capital allocation discipline is a third variable worth watching directly: a $150 million buyback authorization runs through the end of 2026 and was largely untouched as of the most recent quarter, with cash instead directed to the Azstarys deal. Meaningful buyback activity at prices near the current $29.11 — rather than the higher prices at which prior repurchases were executed — would be a concrete signal about how management is actually pricing the stock relative to its own cash flow.

Leverage trajectory is the fourth: net debt/EBITDA sits at 2.1x versus roughly 1x after each of the prior three acquisitions were absorbed. A return toward that historical norm on organic cash generation, without a refinancing, would support the case that the debt-funded acquisition model remains sustainable; a leverage ratio that stays elevated into the next deal would not.

Overall Assessment: COLL FCF Quality Score 7/10

Collegium's free cash flow is mechanically about as clean as this metric gets — FCF/OCF conversion above 94% every year since 2020, capex that has fallen to 0.2% of revenue, and shrinking stock-based compensation. None of that is an illusion, and it is genuinely uncommon for a company screening at a 34.8% trailing yield to also show this little accounting noise in the reconciliation between cash flow and reported free cash flow.

What the multi-year data makes explicit is that the mechanical cleanliness sits on top of a business model where reinvestment happens through acquisition rather than capex. Since 2020, roughly $2.2 billion has gone into four acquisitions against roughly $1.5 billion of cumulative free cash flow generated over the same window, and net debt has swung by more than $1.1 billion as a result. The pain portfolio that anchors current revenue is a decaying asset — Nucynta fell 24% in the most recent quarter alone — and charging the cost of replacing it against operating cash flow cuts the headline 34.8% yield to an owner-earnings figure closer to 11–13%. Both numbers are real; they are answering different questions about the same cash.

A 7/10 score reflects a company with excellent cash-conversion mechanics and a genuinely difficult economic question underneath them, currently priced by the market at the cheapest point in its own eight-year history — no independent peer-yield benchmark could be sourced for this analysis, so that own-history comparison, together with FreeCashFlow.org's broader FCF Screener, is the most direct way to size up where COLL sits today. The FCF Quality Score methodology behind this rating is detailed in Assessing FCF Quality. For context on what a 34.8% trailing yield means relative to typical benchmarks, see What Is a Good Free Cash Flow Yield?. For the mechanics behind the wide gap between FCF and GAAP net income discussed throughout this piece, see Free Cash Flow vs. Net Income, and for the owner-earnings adjustment applied here, see Owner Earnings vs. Free Cash Flow.

⚠️ Disclaimer: This analysis is for educational and informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any recommendation to buy, sell, or hold any security. All financial data is sourced from publicly available SEC filings and is believed to be accurate as of the analysis date but has not been independently audited. Actual results may differ materially from any scenario estimates presented. FCF calculations use operating cash flow minus capital expenditures; alternative definitions may yield different results. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources

• Collegium Pharmaceutical, Inc. Annual Reports (10-K): FY2020–FY2025 — SEC EDGAR XBRL (data.sec.gov)
• Collegium Q2 2026 earnings release and earnings call transcript (August 6, 2026)
• Bloomberg Company Financials (COLL US Equity), pulled August 7, 2026, for historical actuals and 2026E–2027E consensus estimates; share price ($29.11) as of the August 6, 2026 close